Russian Federation: Protecting Biopharmaceutical Inventions In Russia And Eurasia

As in most European countries – where the respective national patent system coexists with a wider European system – the national patent system in Russia coexists with the Eurasian patent system, which comprises eight contracting states. The legislative basis of the Russian patent system is the Civil Code. The Eurasian patent system is based on the Eurasian Patent Convention (1994), which includes (in addition to Russia) seven members of the Commonwealth of Independent States: Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan and Turkmenistan.

Under the Eurasian patent system, a single application is filed with the Eurasian Patent Organisation (EAPO), which grants a patent that is automatically valid in all contracting states, as long as the maintenance fees in each state are paid. The Eurasian patent system applies only to inventions and its official language is Russian. Both patent systems have a wide range of features, including:

  • substantive examination of the patent application (in which industrial applicability, novelty and inventive step are evaluated);
  • appeal and invalidation procedures;
  • the possibility of enforcing patents in court;
  • participation in the Patent Prosecution Highway;
  • patent term extension; and
  • divisional application filing.

When seeking to protect inventions in Russia, the choice between the two patent systems should be informed by a number of factors, including business and marketing interests and costs.

Patentable biopharmaceutical inventions

Both the Russian and Eurasian patent systems provide protection for biopharmaceutical subject matter, including:

  • products, such as compounds, nucleic acids, proteins, cells, cell lines, strains, pharmaceutical compositions, transgenic plants and animals; and
  • use and method claims, such as treatment methods.

The two systems both stipulate that the following are unpatentable:

  • inventions that contravene public interests or principles of humanity and morality;
  • plant varieties; and
  • animal breeds.

In addition, the Russian legislation states that the following are unpatentable:

  • methods of cloning humans and human clones;
  • methods of modifying the genetic integrity of human germline cells; and
  • uses of human embryos for industrial and commercial purposes.

Recent amendments to Russian legislation

A number of amendments to the Russian patent legislation have been adopted in recent years, two of which are particularly relevant to the protection of biopharmaceutical inventions.

Sufficiency of disclosure

questions concerning the necessary extent of disclosure and support in an application will not diminish in importance any time soon, regardless of the part of the legislation to which they are subject


Although the Russian patent legislation previously included a requirement that the specification of an application disclose the invention to a degree sufficient for implementing the invention, the 'sufficiency of disclosure' requirement – as a matter to assess during substantive examination and a legal reason to reject a patent application or invalidate a patent – was introduced into the Civil Code only in 2014. In the context of protecting biopharmaceutical inventions, the Russian Patent Office (Rospatent) has traditionally given great importance to matters concerning the amount of disclosure and support in the specification for inventions claimed. Before this amendment entered into force, evaluation of such matters fell under the evaluation of industrial applicability. Since the amendments are relatively new, there is still little guidance from Rospatent as to how it interprets and enforces the new legislation – in particular, how it distinguishes between matters relating to sufficiency of disclosure and those relating to industrial applicability. In any case, questions concerning the necessary extent of disclosure and support in an application will not diminish in importance any time soon, regardless of the part of the legislation to which they are subject.

Similar sufficiency of disclosure requirements were recently introduced to the Eurasian patent legislation.

Supplementary patents in patent term extension procedure

Pursuant to the Russian legislation, with regard to patents for medicaments, pesticides and agrochemicals that require marketing authorisation, if the term between the filing date and the date of obtaining first marketing authorisation is more than five years, the patent term (20 years) may be extended by that term minus five years on the patent owner's request. The patent term extension cannot exceed five years. Previously, extensions were granted in the form of an enclosure to the actual patent, indicating the independent claims of the patent that concerned the product subject to the first marketing authorisation; said independent claims were extended in full. In accordance with the recent Civil Code amendments, a patent term extension is granted in the form of a supplementary patent with its own set of claims characterising the product that is subject to the marketing authorisation. In order to enforce the new legislation, the Administrative Regulations for Patent Term Extension for Inventions and the Procedure for Issuance and Operation of Supplementary Patents for Inventions and Extension of the Validity Term of Patents for Inventions entered into force in 2016.

Under the Eurasian patent system, the validity term of a Eurasian patent (20 years) may be extended in all contracting states except Tajikistan and Kyrgyzstan. An extension application must be filed with the EAPO within the term stipulated by the legislation of the corresponding state. The patent term extension procedure, terms and necessary documents are stipulated in the legislation of each contracting state. Thus, the validity term of a Eurasian patent may be extended by different terms in different states, or extended in some states but not in others.

Practical considerations during substantive examination

Industrial applicability

Applicants are frequently surprised by Rospatent's approach to evaluating compliance with the industrial applicability requirement for patent grant. Under this approach, the possibility of using the invention in any field is assessed on the basis of the scope of the available experimental data; the examiner considers the possibility of using the invention in any field by seeing whether and to what extent the claimed invention is 'confirmed' by the experimental data. That is, the application materials must confirm implementation of the claimed invention through realisation of the invention's purpose. Evaluation of this matter is part of the evaluation of industrial applicability. Since in most cases the implementation of a claimed invention can be confirmed only by corresponding experimental data, in practice, compliance with this requirement is confirmed by looking at whether the scope of the invention as claimed in each claim is justifiable by the available experimental data plus knowledge of the prior art (which may allow for the scope of the claim to be broadened beyond that of the experimental data). Usually, the examiner raises an industrial applicability objection based on a broadly worded claim feature whose scope goes beyond that which seems justifiable by the available experimental data. This explains why claim breadth has traditionally been linked to the industrial applicability requirement: an 'illegitimately' broad claim or feature is seen as casting doubt on the possibility of implementing the invention for each combination of features within the scope of the claim. For example, the scope of the claim may encompass doubtful or unrealistic combinations of parameters, in which case the invention may not work. This makes the invention inapplicable in industry. In response to an industrial applicability objection, the applicant is expected to justify the chosen scope of the claims or amend them accordingly. Submission of post-priority or post-filing experimental data to confirm the original or desirable scope of the claims is allowed. Thus, contrary to the hopes of some applicants, simple indication of the passage in the specification that forms the language basis for the feature in question is insufficient to address the industrial applicability objection to a broadly worded claim. The takeaway is that it is always better if the claims are reasonably based on the experimental data.

In contrast, the EAPO is largely indifferent to the industrial applicability matter per se. However, objections to an inconsistency between the narrow scope of the available experimental data and the broad scope of the claims are not unusual.

Indication of purpose

Under the Russian legislation, a patent claim directed to virtually any biopharmaceutical product (except for chemical compounds characterised by full structure) must recite a specific purpose of the subject matter claimed. This includes macromolecules, kits, cells, devices, compositions and transgenic organisms. In particular, in cases where oligonucleotides and polypeptides (proteins) are claimed, a biological function (a type of activity, biological property) – which must be indicated for such subject matter – is considered sufficient indication of a purpose (eg, "An antibody against X, comprising..." or "A polynucleotide encoding the protein of claim 1..."). Claims such as "A composition comprising..." or "A method comprising..." will be rejected for lack of purpose. A lack of purpose recited in the claim is interpreted as the possibility of using the claimed subject matter for any possible purpose, which is formally rejected as not completely supported by the specification. Arguing against the requirement to recite a purpose is futile. Naturally, the scope of purpose recited in a claim may be a matter of dispute. For example, the preamble "A pharmaceutical composition comprising..." does contain a mandatory purpose, which is "pharmaceutical" (ie, for medical treatment); however, wording the purpose in such a broad manner may be conceivable only if the composition is useful in the treatment of many different kinds of disease or condition. Since this is never the case, the Russian examiner will require further specification of the purpose – for example, "A pharmaceutical composition for the treatment of colon cancer..." or "A pharmaceutical composition for inhibiting enzyme X...". The purpose of a pharmaceutical composition may be recited in the claim in the form of not only a therapeutic application, but also a biological activity. The same applies to therapeutic method claims, which may be "a method of treatment" or "a method of exerting some biological activity". Claims such as "Use of... in medicine" or "A diagnostic method comprising..." will also be rejected as reciting too broad a purpose.

Antibody subject matter

This is perhaps the most popular kind of protein to claim as an invention. Regarding characterisation of a subject matter directed to a polypeptide (or nucleic acid), the Russian legislation is not very specific, simply requiring recitation of appropriate nucleotide/amino acid sequences (if they are established) or physicochemical and other characteristics that allow for distinguishing the claimed polypeptide from others. If the claimed protein is an antibody (immunoglobulin), the minimal sequence-wise characterisation expected by Rospatent corresponds to recitation of the six complementarity-determining region (CDR) sequences (three light chain and three heavy chain CDR sequences) plus a purpose of the antibody, which may be specific binding to the antigen in question. If no sequences of the antibody are established, in accordance with the aforementioned requirement, the antibody should be characterised with at least one physicochemical feature (eg, a binding constant) and at least one other feature (eg, a method of production). Therefore, contrary to the expectations of some applicants, characterisation of an antibody simply through the epitope that it recognises, another antibody with which it competes for binding to the same antigen or one, two, three, four or five CDR sequences will not be accepted as sufficient. This approach is also used by the EAPO.

Human embryos

Russian legislation does not allow for the patenting of inventions that involve use of human embryos. An absolute taboo is inventions involving the destruction of human embryos. The examiner may also request removal from the specification and claims of any embodiments and experimental data corresponding to use of human embryos. Sometimes, if it is not sufficiently clear from the application materials that the cells used in the invention cannot be human embryonic cells, the applicant may be requested to add to the claim a disclaimer such as "wherein the cell is not a human embryonic cell".

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Gorodissky & Partners
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Gorodissky & Partners
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions